193 related articles for article (PubMed ID: 37676231)
1. Role of Saturation and Length of Fatty Acids of Phosphatidylserine in the Aggregation of Transthyretin.
Ali A; Zhaliazka K; Dou T; Holman AP; Kurouski D
ACS Chem Neurosci; 2023 Sep; 14(18):3499-3506. PubMed ID: 37676231
[TBL] [Abstract][Full Text] [Related]
2. Saturation of fatty acids in phosphatidic acid uniquely alters transthyretin stability changing morphology and toxicity of amyloid fibrils.
Ali A; Zhaliazka K; Dou T; Holman AP; Kurouski D
Chem Phys Lipids; 2023 Nov; 257():105350. PubMed ID: 37858615
[TBL] [Abstract][Full Text] [Related]
3. Secondary structure and toxicity of transthyretin fibrils can be altered by unsaturated fatty acids.
Ali A; Zhaliazka K; Dou T; Holman AP; Kumar R; Kurouski D
Int J Biol Macromol; 2023 Dec; 253(Pt 7):127241. PubMed ID: 37804888
[TBL] [Abstract][Full Text] [Related]
4. Cholesterol and Sphingomyelin Uniquely Alter the Rate of Transthyretin Aggregation and Decrease the Toxicity of Amyloid Fibrils.
Ali A; Zhaliazka K; Dou T; Holman AP; Kurouski D
J Phys Chem Lett; 2023 Dec; 14(49):10886-10893. PubMed ID: 38033106
[TBL] [Abstract][Full Text] [Related]
5. Length and saturation of fatty acids in phosphatidylserine determine the rate of lysozyme aggregation simultaneously altering the structure and toxicity of amyloid oligomers and fibrils.
Frese A; Goode C; Zhaliazka K; Holman AP; Dou T; Kurouski D
Protein Sci; 2023 Aug; 32(8):e4717. PubMed ID: 37402649
[TBL] [Abstract][Full Text] [Related]
6. Nanoscale structural characterization of transthyretin aggregates formed at different time points of protein aggregation using atomic force microscopy-infrared spectroscopy.
Rodriguez A; Ali A; Holman AP; Dou T; Zhaliazka K; Kurouski D
Protein Sci; 2023 Dec; 32(12):e4838. PubMed ID: 37967043
[TBL] [Abstract][Full Text] [Related]
7. The toxicities of A30P and A53T α-synuclein fibrils can be uniquely altered by the length and saturation of fatty acids in phosphatidylserine.
Ali A; Zhaliazka K; Dou T; Holman AP; Kurouski D
J Biol Chem; 2023 Dec; 299(12):105383. PubMed ID: 37890776
[TBL] [Abstract][Full Text] [Related]
8. Uncovering the Mechanism of Aggregation of Human Transthyretin.
Saelices L; Johnson LM; Liang WY; Sawaya MR; Cascio D; Ruchala P; Whitelegge J; Jiang L; Riek R; Eisenberg DS
J Biol Chem; 2015 Nov; 290(48):28932-43. PubMed ID: 26459562
[TBL] [Abstract][Full Text] [Related]
9. Elucidating the Role of Lipids in the Aggregation of Amyloidogenic Proteins.
Kurouski D
Acc Chem Res; 2023 Nov; 56(21):2898-2906. PubMed ID: 37824095
[TBL] [Abstract][Full Text] [Related]
10. Specific disruption of transthyretin(105-115) fibrilization using "stabilizing" inhibitors of transthyretin amyloidogenesis.
Liang Y; Ore MO; Morin S; Wilson DJ
Biochemistry; 2012 Apr; 51(16):3523-30. PubMed ID: 22482799
[TBL] [Abstract][Full Text] [Related]
11. D18G transthyretin is monomeric, aggregation prone, and not detectable in plasma and cerebrospinal fluid: a prescription for central nervous system amyloidosis?
Hammarström P; Sekijima Y; White JT; Wiseman RL; Lim A; Costello CE; Altland K; Garzuly F; Budka H; Kelly JW
Biochemistry; 2003 Jun; 42(22):6656-63. PubMed ID: 12779320
[TBL] [Abstract][Full Text] [Related]
12. Transthyretin suppresses the toxicity of oligomers formed by misfolded proteins in vitro.
Cascella R; Conti S; Mannini B; Li X; Buxbaum JN; Tiribilli B; Chiti F; Cecchi C
Biochim Biophys Acta; 2013 Dec; 1832(12):2302-14. PubMed ID: 24075940
[TBL] [Abstract][Full Text] [Related]
13. Transthyretin Anti-Amyloidogenic and Fibril Disrupting Activities of
Eze FN; Ingkaninan K; Prapunpoj P
Biomolecules; 2019 Dec; 9(12):. PubMed ID: 31835306
[TBL] [Abstract][Full Text] [Related]
14. Trapping the monomer of a non-amyloidogenic variant of transthyretin: exploring its possible use as a therapeutic strategy against transthyretin amyloidogenic diseases.
Palhano FL; Leme LP; Busnardo RG; Foguel D
J Biol Chem; 2009 Jan; 284(3):1443-53. PubMed ID: 18984591
[TBL] [Abstract][Full Text] [Related]
15. Chapter 17: Transthyretin: an enhancer of nerve regeneration.
Fleming CE; Mar FM; Franquinho F; Sousa MM
Int Rev Neurobiol; 2009; 87():337-46. PubMed ID: 19682646
[TBL] [Abstract][Full Text] [Related]
16. Energetic characteristics of the new transthyretin variant A25T may explain its atypical central nervous system pathology.
Sekijima Y; Hammarström P; Matsumura M; Shimizu Y; Iwata M; Tokuda T; Ikeda S; Kelly JW
Lab Invest; 2003 Mar; 83(3):409-17. PubMed ID: 12649341
[TBL] [Abstract][Full Text] [Related]
17. A Brief Journey through Protein Misfolding in Transthyretin Amyloidosis (ATTR Amyloidosis).
Gonzalez-Duarte A; Ulloa-Aguirre A
Int J Mol Sci; 2021 Dec; 22(23):. PubMed ID: 34884963
[TBL] [Abstract][Full Text] [Related]
18. Transthyretin Stabilization: An Emerging Strategy for the Treatment of Alzheimer's Disease?
Saponaro F; Kim JH; Chiellini G
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33212973
[TBL] [Abstract][Full Text] [Related]
19. The Journey of Human Transthyretin: Synthesis, Structure Stability, and Catabolism.
Sanguinetti C; Minniti M; Susini V; Caponi L; Panichella G; Castiglione V; Aimo A; Emdin M; Vergaro G; Franzini M
Biomedicines; 2022 Aug; 10(8):. PubMed ID: 36009453
[TBL] [Abstract][Full Text] [Related]
20. The importance of a gatekeeper residue on the aggregation of transthyretin: implications for transthyretin-related amyloidoses.
Sant'Anna R; Braga C; Varejão N; Pimenta KM; Graña-Montes R; Alves A; Cortines J; Cordeiro Y; Ventura S; Foguel D
J Biol Chem; 2014 Oct; 289(41):28324-37. PubMed ID: 25086037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
